Merck Group's M Ventures unit led the RNA therapy startup's series A round, which featured Amgen, Illumina, AbbVie and Mitsubishi Tanabe Pharma.

US-based RNA drug developer Ribometrix has raised $30m in a series A round led by M Ventures, a corporate venturing vehicle for pharmaceutical firm Merck Group.

AbbVie Ventures, Amgen Ventures, MP Healthcare Venture Management and Illumina Ventures, respective subsidiaries of pharmaceutical companies AbbVie, Amgen and Mitsubishi Tanabe Pharma, and genomics technology provider Illumina, also took part.

The round was filled out by Alexandria Venture Investments, the strategic investment arm of life sciences real estate investment trust Alexandria Real Estate Equities,…